Harry S. Nielsen, Jr., Ph.D. Founder
Prior to joining Nielsen, Dr. Nielsen founded Allermed Laboratories, Inc. and served as President of the company for over 40 years. His interest in the antigenic properties of plants and microorganisms provided the foundation for developing and licensing numerous products in the field of allergy and immunology. His current interests at Nielsen BioSciences, Inc. include the diagnostic and therapeutic use of antigenic materials of Candida albicans and Coccidioides immitis. Dr. Nielsen received his B.S. in Biology and M.S. in Botany from Brigham Young University. Dr. Nielsen received his Ph.D. in Botany and Microbiology from The Ohio State University. He was awarded a National Science Postdoctoral Fellowship in Medical Mycology, which he completed at Duke University. He was a member of the Department of Microbiology and Immunology at Duke University Medical Center where he taught microbiology, mycology, and parasitology.
Thomas R. Carpenter, DVM, Ph.D. President and Chief Executive Officer
Dr. Carpenter brings over 30 years of biomedical research and 15 years of drug development experience. He most recently served as Vice President R&D at Amylin Pharmaceuticals, Inc. overseeing the operations of an innovative research and development portfolio in metabolic disease with over $200M annual budget that led to several successful marketing applications and global alliances. Prior to that, he served as Chief Scientific Officer for LAB Pre-Clinical Research International, Inc., a global CRO serving biotech and major pharma with sites in the Canada, the Netherlands, and Hungary. Dr. Carpenter also established a new CRO facility in San Diego, California. He has been an executive level scientific leader in pharmaceutical companies and contract services organizations as well as an immunology and pharmacology researcher at the University of New Mexico, The Inhalation Toxicology Research Institute, and Colorado State University. He also was a veterinary practitioner for 10 years in small and mixed animal practices.
Scott Nielsen, Vice President Operations
Mr. Nielsen has over 20 years of experience as a financial professional, with over 15 years within the biotech industry. He has executive responsibility for the general business operations of Nielsen BioSciences, Inc. Mr. Nielsen began his career in public accounting with Deloitte in San Diego, where he was a Senior Consultant. He transitioned to the private sector as Controller for Emerald Publications, a marketing company that services the financial industry. He moved to the biotech industry as Vice President of Business Operations at Allermed Laboratories, Inc., a pharmaceutical manufacturer. Mr. Nielsen is a Certified Public Accountant. He received his B.S. in Accounting from Brigham Young University and his MBA from Georgetown University.
Joachim Osther, Sales & Marketing
Joachim Osther is an experienced brand marketing professional who brings over 15 years of pharmaceutical and biotech experience. Mr. Osther has a successful track record that includes leadership in Pharmaceutical Sales, In-Line Marketing and Product Launches for Eli Lilly and Company, Amylin Pharmaceuticals and as an independent Consultant. Most recently he served as the Marketing Director at Amylin Pharmaceuticals for a portfolio of brands with over $1 billion in revenue. Mr. Osther is also a published author on Human Factors and Medical Devices and has been interviewed by Medical Marketing and Media as a subject matter expert. Mr. Osther holds a BA in Exercise Physiology and an AS as a Physical Therapist Assistant from Washburn University. He was Certified as a CPTA by the Kansas State Board of Healing Arts.
Don Rindell, MBA Business Development
Don Rindell has more than 25 years of senior executive experience in the life sciences industry. He has held executive roles in global corporate development, business development and device/technology strategy for several US and European pharmaceutical and medical device companies. Don most recently served as Senior Director of Corporate Development at Amylin Pharmaceuticals, and has led a number of key global transactions with partners including Lilly, Shionogi Pharmaceuticals, BIOCON, and Takeda Pharmaceuticals. Don is a member of the Board of Directors of publicly traded TearLab (NASDAQ: TEAR), and advisor to two other medical device companies. He has previously held senior executivepositions at MDG, CardioNet, Advanced Tissues Sciences, Braun/Thermoscan, and Hybritech. Don received his B.A. degree in Economics from the College of Wooster and an M.B.A. from Pepperdine University Graduate School of Business.
Karen Adam, Head of Quality
Karen Adam serves as a consultant overseeing quality at Nielsen. Ms. Adam brings senior leadership experience in quality, compliance and operations for GMP, GCP, and GLP serving major biotechnology companies for over 20 years. Most recently she served as Sr. Director Quality Compliance at AstraZeneca, (formerly Amylin Pharmaceuticals) for 9 years overseeing manufacturing quality for global pharmaceutical products and drug development efforts. Ms. Adam previously served as Senior Director, Quality at Skye Pharma and as Director, Quality at Pfizer La Jolla. Ms. Adam has a BS in Chemistry from University of Wisconsin, Madison, WI.
Nelson Lugo, Vice President Manufacturing
Nelson Lugo has over twenty five years’ of experience in the areas of biopharmaceutical process development and manufacturing. He most recently served as Sr. Director, Manufacturing and San Diego Site Lead for AstraZeneca PLC. Mr. Lugo has worked in process development and manufacturing of products derived from multiple sources. He has managed the technology transfer of products from R&D into Commercial and has overseen multiple contract CMOs for DS (API), fill/finish operations and secondary packaging sites. He has managed the technology transfer at XOMA (US) LLC, Scios, Inc., and Amylin Pharmaceuticals, Inc. He’s directed the manufacturing operations for Melville Biologics, Dendreon Corporation and ISTA Pharmaceuticals, Inc. He has been a guest lecturer at the University of California, Berkeley covering issues in Manufacturing. Mr. Lugo authored an article on the “Management Life Cycle Process” published in the Oct’09 issue of “Contract Pharma” magazine. Mr. Lugo received his Bachelor’s degree in Clinical Chemistry from York College, New York and holds an MBA from Adelphi University, New York.
© 2014 Nielsen BioSciences, Inc.
CANDIN®, ALBICIN®, and SPHERUSOL® are trademarks of Nielsen BioSciences, Inc. All other trademarks are the property of their respective owners.
The following third-party website was provided for your convenience, and Nielsen BioSciences, Inc. does not endorse, verify, or otherwise support the information contained in these websites. You are subject to the legal terms and conditions of use for third-party websites.